Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice; Makary’s Priority Voucher Pilot Launches, Mentions Innovative PTSD Treatments; HALT Fentanyl Act Could Streamline Schedule I Research
Norway’s Health System Considers Funding Off-Label Ketamine for Treatment-Resistant Depression • Spravato’s Monotherapy Success Puts Pressure on Psychedelics Developers • Longevity Crowd Hypes Psilocybin Study But Researchers Urge Caution • Will State-Legal Psychedelics Eat Psychedelic Pharma’s Lunch? • 3 Years of Psychedelics Access via Canada’s Special Access Programme • The New Neuroplastogen Developer on the Block • and more…